Whitney & Co’s Genomic Health, Inc. GHDX Stock Holding History

Whitney & Co’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-29	Closed	-$2K	–	526
2018 Q3	$2K	Buy	+29	New	+$1.7K	﹤0.01%	492

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Whitney & Co's GHDX Position: Q4 2018 in Review

Whitney & Co sold out of Genomic Health, Inc. (GHDX) in Q4 2018, closing a stake of 29 shares — an estimated $2K sold.

Whitney & Co first reported a position in GHDX in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 228 funds tracked by Wall St. Rank hold GHDX as of Q4 2018.

Whitney & Co reported no remaining Genomic Health, Inc. position as of Q4 2018 after selling out during the quarter.
Whitney & Co sold 29 Genomic Health, Inc. shares in Q4 2018, an estimated $2K.
Whitney & Co first reported a position in Genomic Health, Inc. in Q3 2018 and held it in 1 quarter.
Whitney & Co's Genomic Health, Inc. position peaked at $2K in Q3 2018.
228 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.